42,081 Shares in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Acquired by Diadema Partners LP

Diadema Partners LP bought a new position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 42,081 shares of the company's stock, valued at approximately $351,000. Diadema Partners LP owned about 0.08% of Zevra Therapeutics at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Geode Capital Management LLC increased its stake in shares of Zevra Therapeutics by 14.2% during the third quarter. Geode Capital Management LLC now owns 1,043,864 shares of the company's stock valued at $7,246,000 after buying an additional 129,600 shares during the period. Barclays PLC raised its stake in Zevra Therapeutics by 292.6% in the third quarter. Barclays PLC now owns 57,599 shares of the company's stock worth $399,000 after buying an additional 42,926 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in Zevra Therapeutics in the fourth quarter worth about $224,000. Rhumbline Advisers grew its holdings in shares of Zevra Therapeutics by 18.4% during the 4th quarter. Rhumbline Advisers now owns 68,053 shares of the company's stock worth $568,000 after acquiring an additional 10,573 shares during the period. Finally, Vanguard Group Inc. raised its position in shares of Zevra Therapeutics by 2.5% in the 4th quarter. Vanguard Group Inc. now owns 2,824,212 shares of the company's stock worth $23,554,000 after acquiring an additional 68,151 shares in the last quarter. Hedge funds and other institutional investors own 35.03% of the company's stock.

Zevra Therapeutics Stock Performance

Shares of Zevra Therapeutics stock traded down $0.04 during trading on Friday, hitting $7.20. 381,265 shares of the company's stock traded hands, compared to its average volume of 610,289. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.88 and a quick ratio of 2.88. The stock has a market capitalization of $393.69 million, a P/E ratio of -3.65 and a beta of 1.94. The business has a 50-day simple moving average of $7.52 and a 200-day simple moving average of $8.12. Zevra Therapeutics, Inc. has a 1 year low of $4.20 and a 1 year high of $9.76.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last released its quarterly earnings data on Tuesday, March 11th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.28). Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. The company had revenue of $12.00 million for the quarter, compared to analysts' expectations of $8.93 million. As a group, analysts forecast that Zevra Therapeutics, Inc. will post -1.95 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have issued reports on ZVRA. Cantor Fitzgerald reiterated an "overweight" rating and issued a $25.00 price objective on shares of Zevra Therapeutics in a report on Wednesday, March 12th. Citigroup reissued an "outperform" rating on shares of Zevra Therapeutics in a research note on Wednesday, March 12th. JMP Securities set a $18.00 target price on shares of Zevra Therapeutics in a research note on Wednesday, March 12th. Guggenheim lifted their target price on shares of Zevra Therapeutics from $20.00 to $22.00 and gave the company a "buy" rating in a report on Thursday, March 13th. Finally, Canaccord Genuity Group upped their price target on Zevra Therapeutics from $23.00 to $25.00 and gave the stock a "buy" rating in a research note on Thursday, March 13th. Eight equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $22.29.

Insider Activity at Zevra Therapeutics

In other Zevra Therapeutics news, Director John B. Bode acquired 10,000 shares of the business's stock in a transaction dated Wednesday, March 19th. The stock was purchased at an average price of $7.96 per share, with a total value of $79,600.00. Following the transaction, the director now directly owns 40,000 shares in the company, valued at approximately $318,400. The trade was a 33.33 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Neil F. Mcfarlane sold 61,273 shares of the company's stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total value of $481,605.78. Following the completion of the sale, the chief executive officer now owns 222,060 shares of the company's stock, valued at $1,745,391.60. This trade represents a 21.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 85,773 shares of company stock worth $674,176. 2.40% of the stock is owned by insiders.

Zevra Therapeutics Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.